Tourmaline Bio, Inc. (TRML)
Largest Insider Buys in Sector
TRML Stock Price History Chart
TRML Stock Performance
About Tourmaline Bio, Inc.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
Insider Activity of Tourmaline Bio, Inc.
Over the last 12 months, insiders at Tourmaline Bio, Inc. have bought $3.35M and sold $0 worth of Tourmaline Bio, Inc. stock.
On average, over the past 5 years, insiders at Tourmaline Bio, Inc. have bought $3.35M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: MCDADE MARK (director) — $3.25M. Kulkarni Sandeep Chidambar (CEO) — $98,416.
The last purchase of 1,779 shares for transaction amount of $26,418 was made by Kulkarni Sandeep Chidambar (CEO) on 2024‑08‑21.
List of Insider Buy and Sell Transactions, Tourmaline Bio, Inc.
| 2024-08-21 | CEO | 1,779 0.004% | $14.85 | $26,418 | +71.70% | |||
| 2024-08-16 | CEO | 5,221 0.0108% | $13.79 | $71,998 | +79.08% | |||
| 2024-01-29 | director | 100,000 0.4867% | $32.50 | $3.25M | -42.50% |